Misplaced Pages

Olsalazine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Pharmaceutical drug
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Olsalazine" – news · newspapers · books · scholar · JSTOR (January 2021) (Learn how and when to remove this message)
Pharmaceutical compound
Olsalazine
Clinical data
Trade namesDipentum
AHFS/Drugs.comMonograph
MedlinePlusa601088
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Protein binding99%
Elimination half-life0.9 hours
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.116.494 Edit this at Wikidata
Chemical and physical data
FormulaC14H10N2O6
Molar mass302.242 g·mol
3D model (JSmol)
SMILES
  • O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
InChI
  • InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+
  • Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N
  (what is this?)  (verify)

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.

Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.

History

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply

The drug is supplied by UCB Pharma.

Research

In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.

References

  1. ^ "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
  2. "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID 2131213. S2CID 7178709.
  3. Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID 1711964. S2CID 243654426.
  4. ^ "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
  5. "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.
Antidiarrheals, intestinal anti-inflammatory and anti-infective agents (A07)
Rehydration
Intestinal anti-infectives
Intestinal adsorbents
Antipropulsives (opioids)
Intestinal anti-inflammatory agents
Antidiarrheal micro-organisms
Other antidiarrheals
Portal: Categories: